These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10597772)

  • 41. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.
    Thiébaut R; Daucourt V; Mercié P; Ekouévi DK; Malvy D; Morlat P; Dupon M; Neau D; Farbos S; Marimoutou C; Dabis F
    Clin Infect Dis; 2000 Dec; 31(6):1482-7. PubMed ID: 11096016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.
    Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F;
    HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease: Aquitaine Cohort, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
    Binquet C; Saillour F; Bernard N; Rougier MB; Leger F; Bonnal F; Dabis F
    Eur J Epidemiol; 2000 May; 16(5):425-32. PubMed ID: 10997829
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy].
    Lana R; Núñez M; Mendoza JL; Soriano V
    Med Clin (Barc); 2001 Nov; 117(16):607-10. PubMed ID: 11714465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002).
    Martin K; Lawson-Ayayi S; Miremont-Salamé G; Blaizeau MJ; Balestre E; Lacoste D; Ragnaud JM; Malvy D; Dupon M; Mercié P; Schaeverbeke T; Haramburu F; Dabis F;
    HIV Med; 2004 Nov; 5(6):421-6. PubMed ID: 15544694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
    Dore G
    J HIV Ther; 2003 Nov; 8(4):96-100. PubMed ID: 14671507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
    Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
    J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
    Dieleman JP; Jambroes M; Gyssens IC; Sturkenboom MC; Stricker BH; Mulder WM; de Wolf F; Weverling GJ; Lange JM; Reiss P; Brinkman K;
    AIDS; 2002 Mar; 16(5):737-45. PubMed ID: 11964530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.
    Taramasso L; Lorenzini P; Di Biagio A; Lichtner M; Marchetti G; Rossotti R; Lapadula G; Cozzi-Lepri A; Vichi F; Antinori A; Bonora S; d'Arminio Monforte A;
    J Antimicrob Chemother; 2019 Nov; 74(11):3295-3304. PubMed ID: 31504633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
    Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R
    Clin Infect Dis; 2010 Feb; 50(4):502-11. PubMed ID: 20085465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort.
    Ratnam I; Chiu C; Kandala NB; Easterbrook PJ
    Clin Infect Dis; 2006 Feb; 42(3):418-27. PubMed ID: 16392092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.